Previous Mitral Valve Replacement
To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic (tissue) valve who are an intermediate surgical risk.
Principal Investigators: Robert L. Smith, II, MD / Molly Szerlip, MD
Locations: Baylor Scott & White The Heart Hospital – Plano
IRB Number: 017-468
Trial Status: Enrolling
Exclusions: Adults only
Change in Care:
Necole Kell, RN469.814.4871Necole.Kell@BSWHealth.org
Brittany Zingler, RN469.814.4737Brittany.Zingler@BSWHealth.org
A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Requiring Aortic Valve Replacement who have Severe, Calcific, Symptomatic Aortic Stenosis
Get Detailed Information On Clinicaltrials.gov »
Physicians are members of the medical staff at one of Baylor Health Care System's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor Scott & White The Heart Hospital – Plano or Baylor Health Care System.